Lipocine Received Notice From Antares Of Antares' Termination Of The License Agreement; Terms Say The License Agreement Will Terminate Effective Jan. 31, 2024
Portfolio Pulse from Benzinga Newsdesk
Lipocine Inc. (LPCN) has received a termination notice from Antares Pharma for their license agreement, which will be effective from January 31, 2024.
October 06, 2023 | 8:12 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Lipocine Inc. has received a termination notice from Antares Pharma for their license agreement, which will be effective from January 31, 2024.
The termination of the license agreement with Antares Pharma could potentially impact Lipocine's revenue and business operations. This could lead to a negative sentiment among investors, potentially driving the stock price down in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100